| Dexlansoprazole MR for the management of gastroesophageal reflux disease. | |
| | |
MedLine Citation:
|
PMID: 21780890 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Dexlansoprazole modified release (MR; Dexilant™), the R-enantiomer of lansoprazole, was approved in the USA in 2009 for the management of erosive esophagitis and nonerosive reflux disease. Dexlansoprazole MR has a unique dual delayed-release delivery system that was designed to address unmet needs that may accompany the use of single-release proton pump inhibitors (PPIs), specifically, their short plasma half-life and requirement for meal-associated dosing. The delivery technology of dexlansoprazole MR is designed to release the drug in two separate pH-dependent phases, the first in the proximal duodenum and the second in the more distal small intestine. This extends plasma concentration and pharmacodynamic effects of dexlansoprazole MR beyond those of single-release PPIs and allows for dosing at any time of the day without regard to meals. This added convenience, along with excellent healing of esophagitis and symptom relief, substantiate its use in patients with gastroesophageal reflux disease requiring PPI treatment. |
| | |
Authors:
|
Brian W Behm; David A Peura |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert review of gastroenterology & hepatology Volume: 5 ISSN: 1747-4132 ISO Abbreviation: Expert Rev Gastroenterol Hepatol Publication Date: 2011 Aug |
Date Detail:
|
Created Date: 2011-07-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101278199 Medline TA: Expert Rev Gastroenterol Hepatol Country: England |
Other Details:
|
Languages: eng Pagination: 439-45 Citation Subset: IM |
Affiliation:
|
University of Virginia Health Science Center, PO Box 800708, Charlottesville, VA 22908, USA. bwb2c@virginia.edu. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Rectification of miscalculation of adalimumab costs.
Next Document: Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose ace...